Related Experiment Videos
[New approaches to the study of thrombocyte aggregation in patients with dilated cardiomyopathy]
Insights
Platelet aggregation increases with heart failure (HF) severity in dilated cardiomyopathy (DCMP) patients. A novel aggregometer detected heightened platelet activity even at early HF stages, indicating potential for early intervention.
Area of Science:
- Cardiology
- Hematology
- Biomedical Engineering
Background:
- Dilated cardiomyopathy (DCMP) is associated with altered hemostasis.
- Platelet activation plays a role in cardiovascular disease progression.
- Assessing platelet function in heart failure (HF) requires sensitive methodologies.
Purpose of the Study:
- To evaluate platelet aggregation in DCMP patients across different HF stages.
- To investigate the utility of a highly sensitive aggregometer for studying platelet function.
- To determine the relationship between HF severity and platelet aggregation.
Main Methods:
- Utilized a highly sensitive aggregometer capable of detecting responses to low-dose agonists.
- Studied platelet aggregation in DCMP patients with varying HF stages (0-I, IIA, IIB-III).
- Administered low concentrations of adenosine diphosphate (ADP) and platelet aggregation factor.
Main Results:
- Significantly increased platelet aggregation observed in response to 0.1 microM ADP in DCMP patients with HF stages 0-I and IIA.
- Platelet aggregation progressively increased with advancing HF stages.
- Higher ADP concentrations (0.2-0.5 microM) and platelet aggregation factor did not elevate aggregation in early HF stages, but showed a lesser increase in advanced HF stages (IIB-III).
Conclusions:
- A sensitive aggregometer can detect enhanced platelet aggregation in early-stage DCMP with HF.
- Platelet hyper-reactivity correlates with HF severity in DCMP.
- These findings suggest potential for early detection and therapeutic targeting of platelet activation in DCMP.
Abstract:
A degree of platelet aggregation in patients with dilatation cardiomyopathy (DCMP) with different stages of heart failure (HF) was evaluated with the help of a highly sensitive aggregometer developed in the All-Union Cardiological Research Center AMS USSR. The main advantage of this modification was a possibility to study platelet aggregation in response to small doses of an inductor (e.g. less than 0.2 microM of ADP) that could not be done using routine methods. A significant rise of a degree of platelet aggregation was revealed in patients with 0-I,IIA stages of DCMP and IIB-III stages of HF in response to 0.1 microM of ADP. Platelet aggregation was enhanced with an increase in a HF stage. The addition of a higher concentration of ADP (0.2-0.5 microM) and the platelet aggregation factor (5 and 25 nM) revealed no rise of platelet aggregation in patients with 0-I stages of DCMP and IIA stage of HF. Only in patients with stages IIB-III of HF was a platelet aggregation index significantly raised in response to 0.2 and 0.5 microM of ADP but to a much lesser degree than in the addition of 0.1 microM of ADP.